Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

被引：7

作者：

Diefenbach, Catherine S. ^{[1
]}

Jegede, Opeyemi ^{[2
]}

Ansell, Stephen M. ^{[3
]}

Steidl, Christian ^{[4
]}

Natkunam, Yasodha ^{[5
,6
]}

Scott, David W. ^{[7
]}

Mehta-Shah, Neha ^{[8
]}

Amengual, Jennifer E. ^{[9
]}

Forlenza, Christopher J. ^{[10
]}

Cole, Peter D. ^{[11
]}

Bartlett, Nancy L. ^{[12
]}

David, Kevin A. ^{[13
]}

Advani, Ranjana H. ^{[14
]}

Ambinder, Richard F. ^{[15
]}

Thomas, Sachdev ^{[16
]}

Ibrahimi, Sami ^{[17
]}

Kahl, Brad S. ^{[18
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[2] CIMAC CIDC Network, Dept Data Sci, Boston, MA USA

[3] Mayo Clin, Div Hematol, Rochester, MN USA

[4] BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada

[5] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA USA

[6] Stanford Univ, Med Ctr, Stanford, CA USA

[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada

[8] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[9] Columbia Univ, Div Hematol & Oncol, Lymphoma Program, Irving Med Ctr, New York, NY USA

[10] Mem Sloan Kettering Canc Ctr, West Harrison, NY USA

[11] NJ Rbt Wood Johnson Univ Hosp, Rutgers Ca Inst, New Brunswick, NJ USA

[12] Washington Univ, Siteman, Sch Med, St Louis, MO USA

[13] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[14] Stanford Univ, Div Hematol & Oncol, Dept Med, Stanford, CA USA

[15] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[16] VA Cent Calif Hlth CARE Syst, Fresno, CA USA

[17] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[18] Washington Univ, Sch Med St Louis, St Louis, MO USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-184531

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] B-CAP (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and predniso(lo)Ne) in older patients with advanced-stage hodgkin lymphoma: results of a phase II intergroup trial By the German Hodgkin study group (GHSG) and the Nordic Lymphoma group (NLG)
Boell, B.
Fossa, A.
Goergen, H.
Kamper, P.
Leppa, S.
Molin, D.
Meissner, J.
Ritter, E.
Christensen, J. H.
Hutchings, M.
Fuchs, M.
Engert, A.
Borchmann, P.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 161 - 161
[42] B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)
Boell, Boris
Fossa, Alexander
Goergen, Helen
Kamper, Peter
Leppa, Sirpa
Molin, Daniel
Meissner, Julia
Ritter, Ellen
Christensen, Jacob H.
Hutchings, Martin
Fuchs, Michael
Engert, Andreas
Kobe, Carsten
Borchmann, Peter
BLOOD, 2018, 132
[43] Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
Tournilhac, Olivier
Hacini, Maya
Bouabdallah, Kamal
Laribi, Kamel
Maerevoet, Marie
Ysebaert, Loic
Guidez, Stephanie
Le Gouill, Steven
Andre, Marc
Dupuis, Jehan
Thieblemont, Catherine
Bachy, Emmanuel
Daguindau, Nicolas
Morschhauser, Franck
Tricot, Sabine
Feugier, Pierre
Banos, Anne
De la Chapelle, Thierry Lamy
Chauchet, Adrien
Gyan, Emmanuel
Cartron, Guillaume
Farhat, Hassan
Camus, Vincent
Drenou, Bernard
Zerazhi, Hacene
Sibon, David
Nicolas-Virelizier, Emmanuelle
Delette, Caroline
Snauwaert, Sylvia
Straetmans, Nicole
Delarue, Richard
Parrens, Marie
Bossard, Celine
De Leval, Laurence
Gaulard, Philippe
Damaj, Gandhi Laurent
BLOOD, 2020, 136
[44] A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Kunz, Pamela L.
Catalano, Paul J.
Nimeiri, Halla Sayed
Fisher, George A.
Longacre, Teri A.
Schrijver, Iris
Reidy, Diane Lauren
Strosberg, Jonathan R.
O'Dwyer, Peter J.
Benson, Al Bowen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[45] Nivolumab Combined With Brentuximab Vedotin for Relapsed/ Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results From the Phase 2 CheckMate 436 Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 12 - 13
[46] Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial
Moskowitz, Alison J.
Santoro, Armando
Gritti, Giuseppe
Brice, Pauline
Cunningham, David
Barr, Paul
Kline, Justin
Kuruvilla, John
Johnson, Nathalie A.
Mehta-Shah, Neha
Manley, Thomas
Sharma, Manish
Francis, Stephen
Cohen, Joseph
Zinzani, Pier Luigi
BLOOD, 2018, 132
[47] Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
Carthon, Bradley C.
Kim, Se Eun
Mcdermott, David F.
Dutcher, Janice P.
Puligandla, Maneka
Manola, Judith
Pins, Michael
Carducci, Michael A.
Plimack, Elizabeth R.
Appleman, Leonard J.
Macvicar, Gary R.
Kohli, Manish
Kuzel, Timothy M.
Dipaola, Robert S.
Haas, Naomi B.
CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : 546 - 554
[48] Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Zinzani, Pier Luigi
Santoro, Armando
Gritti, Giuseppe
Brice, Pauline
Barr, Paul M.
Kuruvilla, John
Cunningham, David
Kline, Justin
Johnson, Nathalie A.
Mehta-Shah, Neha
Manley, Thomas
Francis, Stephen
Sharma, Manish
Moskowitz, Alison J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (33) : 3081 - +
[49] Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children's Oncology Group (COG) report.
Cole, Peter D.
McCarten, Kathleen
Metzger, Monika
Drachtman, Richard A.
Horton, Terzah M.
Pei, Qinglin
Bush, Rizvan
Blaney, Susan
Weigel, Brenda
Kelly, Kara M.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[50] Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study
Stamatoullas, Aspasia
Ghesquieres, Herv
Filliatre, Lauriane Clement
Quittet, Philippe
Morschhauser, Franck
Ribrag, Vincent
Edeline, Veronique
Brice, Pauline
BLOOD, 2019, 134

← 1 2 3 4 5 →